Cancer Clinical Trial
Official title:
Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy
Background:
- Fatigue is a very common early and late side effect of cancer treatment, including
radiation therapy. The cause of fatigue is poorly understood, making it hard to diagnose and
treat. More research is necessary to understand why patients receiving cancer treatment
experience fatigue. Changes in mitochondria, parts of body cells that help provide energy to
the cell, may contribute to fatigue. Researchers are interested in looking at blood chemicals
and mitochondrial genes of cancer patients to study those associated with fatigue.
Objectives:
- To study the relationship between fatigue and the effects of cancer treatment.
Eligibility:
- Men at least 18 years of age who have been diagnosed with localized prostate cancer and
are scheduled to receive external beam radiation therapy.
- Participants on study 09-NR-0088, Molecular-Genetic Correlates of Fatigue in Cancer
Patients Receiving External Beam Radiation Therapy, are also eligible.
Design:
- This study requires three outpatient visits to the NIH Clinical Center.
- Participants will be seen before they start radiation treatment, at the middle of
treatment, and at the end of treatment. Each visit will take less than 30 minutes to
complete.
- Participants will complete questionnaires that ask about fatigue and depression.
- Participants will provide blood samples for research testing and potential HIV testing.
- No treatment will be provided as part of this protocol.
Fatigue is a common early and chronic adverse effect of radiation but its correlates and
prevalence are poorly understood. Over 40% of cancer patients receive radiation therapy
during the management of their disease. While external beam intensity modulated radiation
therapy (EBRT/IMRT) successfully increases disease-free survival rates and life expectancy,
ionizing radiation leads to increased treatment-related adverse effects including fatigue.
Multidimensional causes and mechanisms of cancer-related fatigue remain unclear, and early
biomarkers prognostic for radiation-induced fatigue have not been identified.
There is evidence that an increase in reactive oxygen species (ROS) formation will cause
cellular damage resulting in dysfunction to mitochondria. ROS are considered one of the major
direct causes of ionizing radiation-induced damage, resulting in a number of adverse effects
(e.g. fatigue, nausea, vomiting, diarrhea, peripheral neuropathy, and cognitive function
impairment) that reduce the efficacy of treatment. Mitochondrial dysfunction is involved in
all clinical conditions including fatigue which are associated with the deficient energy
metabolism of oxidative phosphorylation. Mitochondria are vulnerable to ROS which are
generated endogenously (e.g. mitochondrial superoxide) and exogenously (e.g. ionizing
radiation, inflammation). Once mitochondrial proteins are damaged, the affinity of substrates
or enzymes is decreased resulting in mitochondrial dysfunction including reduced ATP
production, increased ROS generation, and initiated apoptosis signaling. While mitochondrial
dysfunction has been implicated in a variety of clinical fatigue states, the physiological
pathways and pathophysiological mechanisms are complicated and remain unclear.
The primary purpose of this study is to explore the relationships between mitochondrial
dysfunction and fatigue in prostate cancer patients receiving EBRT. Specific aims include:
(1) identify mitochondrial-related gene expression profile changes over time; (2) quantify
the severity of perceived fatigue before, during and at the end of radiation therapy; (3)
determine possible pathways and early biomarkers of mitochondrial dysfunction related to
fatigue in patients with prostate cancer receiving EBR. Blood samples and self-administrated
questionnaires are collected at baseline, midpoint and the end of EBRT. Human mitochondrial
PCR array will be utilized to identify differential regulation of genes involved in
mitochondrial dysfunction at the different time points compared with gene expression from the
baseline samples.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|